Skip to main content
. 2012 Oct 1;122(10):3448–3455. doi: 10.1172/JCI61205

Figure 2. Schematic representation of the PDGF/PDGFR signaling pathway (Generated using MetaCore software; GeneGo Inc.).

Figure 2

Notably, different key points of PDGFR signaling can be the object of pharmacological inhibition. First, PDGFRs can be directly blocked by TKIs. Second, the immediate downstream JAK/STAT pathway, SRC kinase and PI3K can be selectively disrupted. Finally, in cases retaining NF-κB activity (around 30% of PTCL-NOSs), different molecules might be targeted. Adapted with permission from Expert Review of Hematology (59).